Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

AIMS: Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit across a range of renal function. We determined w...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Heart J
Egile Nagusiak: Tuñón, José, Steg, Philippe Gabriel, Bhatt, Deepak L, Bittner, Vera A, Díaz, Rafael, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Li, Qian H, Mueller, Christian, Parkhomenko, Alexander, Pordy, Robert, Sritara, Piyamitr, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Clinical Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7700757/
https://ncbi.nlm.nih.gov/pubmed/32820320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa498
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak